氢化可的松琥珀酸钠结构式
|
常用名 | 氢化可的松琥珀酸钠 | 英文名 | Corlan |
|---|---|---|---|---|
| CAS号 | 125-04-2 | 分子量 | 484.51 | |
| 密度 | N/A | 沸点 | 685.5ºC at 760mmHg | |
| 分子式 | C25H33NaO8 | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 231.1ºC |
氢化可的松琥珀酸钠用途Hydrocortisone hemisuccinate sodium 是一种有口服活性的生理性糖皮质激素。Hydrocortisone hemisuccinate sodium 抑制 IL-6 和 IL-3 的生物活性,IC50 值分别为 6.7 和 21.4 μM。Hydrocortisone hemisuccinate sodium 可用于溃疡性结肠炎 (UC) 的研究。 |
| 中文名 | 氢化可的松琥珀酸钠 |
|---|---|
| 英文名 | Hydrocortisone Hemisuccinate Sodium Salt |
| 中文别名 | 氢化可的松21-半琥珀酸钠盐 | 皮質醇 |
| 英文别名 | 更多 |
| 描述 | Hydrocortisone hemisuccinate sodium 是一种有口服活性的生理性糖皮质激素。Hydrocortisone hemisuccinate sodium 抑制 IL-6 和 IL-3 的生物活性,IC50 值分别为 6.7 和 21.4 μM。Hydrocortisone hemisuccinate sodium 可用于溃疡性结肠炎 (UC) 的研究。 |
|---|---|
| 相关类别 | |
| 体外研究 | 半琥珀酸氢化可的松抑制IL-6和IL-3的生物活性,IC50分别为6.7和21.4μM,对IL-6非依赖性MH60细胞没有细胞毒性作用[3]。半琥珀酸氢化可的松钠(0.12-60μM；72小时)抑制外周淋巴细胞(PBL)和T淋巴细胞培养物中的植物血凝素(PHA)反应[3]。 |
| 体内研究 | 半琥珀酸氢化可的松钠(30 mg/kg；每天两次,持续5天)可减少小鼠的体重减轻并增加食物摄入量[2]。动物模型：雄性Sprague-Dawley大鼠(200-220 g,10-11周)诱导结肠炎[2]剂量：30 mg/kg给药：每天两次,持续5天结果：与2,4,6-三硝基苯磺酸(TNBS)组相比,疾病活动指数(DAI)评分和髓过氧化物酶(MPO)活性显著降低。增加了体重。 |
| 参考文献 |
| 沸点 | 685.5ºC at 760mmHg |
|---|---|
| 分子式 | C25H33NaO8 |
| 分子量 | 484.51 |
| 闪点 | 231.1ºC |
| 精确质量 | 484.207306 |
| PSA | 141.03000 |
| LogP | 0.86260 |
| 外观性状 | powder |
| 蒸汽压 | 9.36E-22mmHg at 25°C |
| 储存条件 | −20℃。 |
| 水溶解性 | H2O: 50 mg/mL |
| 更多 | 1.性状：粉末。 2.溶解度：H2O: 50 mg/mL。 |
| 个人防护装备 | Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter |
|---|---|
| 危害码 (欧洲) | Xi |
| 危险品运输编码 | NONH for all modes of transport |
| WGK德国 | 3 |
| RTECS号 | GM9015000 |
|
Daily endogenous cortisol production and hydrocortisone pharmacokinetics in adult horses and neonatal foals.
Am. J. Vet. Res. 73(1) , 68-75, (2012) To compare daily endogenous cortisol production rate and the pharmacokinetics of an i.v. bolus of hydrocortisone between neonatal foals and adult horses.10 healthy full-term 2- to 4-day-old foals and ... |
|
|
The compatibility of a low concentration of hydrocortisone sodium succinate with selected drugs during a simulated Y-site administration.
Crit. Care Resusc. 15(1) , 63-6, (2013) Bolus dose concentrations of hydrocortisone (50mg/mL) are reported to be incompatible with midazolam and ciprofloxacin in Y-site mixing studies. We evaluated the physical and chemical compatibility of... |
|
|
Glucocorticoids decrease serum adiponectin level and WAT adiponectin mRNA expression in rats.
Steroids 75(12) , 853-8, (2010) Accumulating evidence suggests that adiponectin plays an important role in the genesis of obesity and insulin resistance. Although it has been shown that glucocortocoids (GC) inhibit adiponectin expre... |
| Pregn-4-ene-3,20-dione, 21-(3-carboxy-1-oxopropoxy)-11,17-dihydroxy-, monosodium salt, (11β)- |
| Sodium 4-{[(11β)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl]oxy}-4-oxobutanoate |
| Solu-Glyc |
| Butanedioic acid, mono[(11β)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl] ester, sodium salt (1:1) |
| Hydrocortisone hemisuccinate sodium salt |
| Natrium-4-{2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy}-4-oxobutanoat |
| Intracort |
| Hydrocortisone sodium succinate |
| MFCD00069472 |
| (11b)-21-(3-Carboxy-1-oxopropoxy)-11,17-dihydroxypregn-4-ene-3,20-dione Monosodium Salt |
| Saxizon |
| EINECS 204-725-5 |
| Buccalsone |
| butanedioic acid, mono[(11β)-11,17-dihydroxy-3,20-dioxopregn-4-en-21-yl] ester, monosodium salt |
| Hydrocortisone 21-sodium succinate |
| Corlan |
| sodium 4-{2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-dimethyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-oxoethoxy}-4-oxobutanoate |
| Nordicort |
| 4-{2-[(8S,9S,10R,11S,13S,14S,17R)-11,17-dihydroxy-10,13-diméthyl-3-oxo-2,3,6,7,8,9,10,11,12,13,14,15,16,17-tétradécahydro-1H-cyclopenta[a]phénanthrén-17-yl]-2-oxoéthoxy}-4-oxobutanoate de sodium |
| Sodium 17-hydroxycorticosterone 21-succinate |
查看所有供应商和价格请点击：